The global atrial fibrillation market size is expected to reach USD 2.11 Billion in 2028 at a CAGR of 6.4% during the forecast period, according to the latest report by Reports and Data. Increasing global prevalence of Atrial Fibrillation (AFib) due to rising incidence of cardiovascular diseases and other chronic conditions, technological advancements in atrial fibrillation devices, and increasing product approvals from FDA for treatment of atrial fibrillation are key factors expected to drive market revenue growth over the forecast period. In addition, rapid advancements in clinical treatment of atrial fibrillation and availability of advanced medical devices are further expected to drive revenue growth of the market going ahead.

Atrial fibrillation is the most common type of cardiac arrhythmia with a global prevalence of nearly 2%. Atrial fibrillation is a supraventricular tachyarrhythmia caused to abnormal electrical activity that leads to uncoordinated atrial activation and uncoordinated atrial contraction. Atrial fibrillation results in a turbulent and abnormal blood flow through chambers of the heart, which in turn, results in decreased effectiveness of the heart to pump blood. Uncoordinated atrial contraction decreases the cardiac output by nearly 20% and this is further exacerbated in mitral stenosis, hypertension, and impaired diastolic ventricular filling, among other conditions. Atrial fibrillation can be asymptomatic or symptomatic, with symptoms including chest pain, dizziness, nausea, fast heart rate, and generalized fatigue. Advanced age, high blood pressure, congenital heart disease, and underlying heart and lung disorders are some major risk factors for atrial fibrillation. Over the recent years, extensive research development projects is resulting in development of advanced clinical treatment of atrial fibrillation and risk modifying strategies to minimize the risk of stroke and other cardiac complications in patients with AFib.

Top Companies Profiled in the Report Include:

The global atrial fibrillation market is slightly fragmented with presence of large number of players operating on a global and regional scale. Key players are engaged in product development and strategic alliances to cater to growing global demand and gain a robust footing in the market. Major companies profiled in the global market report include Abbott Laboratories, Atricure Inc., Johnson Johnson, Microport Scientific Corporation, Boston Scientific Corporation, Biosense Webster, Inc., St. Jude medical, Inc., Siemens AG, Medtronic Plc, Koninklijke Philips N.V., Cardiofocus, Inc., Biotitic Se Co. Kg, Inc., Carima, Inc., Ncontact, Inc., and Agricore, Inc.

Atrial Fibrillations Market Overview:

The pharma and healthcare industry has undergone a revolutionary change owing to the COVID-19 pandemic with individuals increasing their focus on health and wellness. Companies operating in the industry have invested heavily in clinical trials and research studies to develop medications to cater to the growing unmet clinical demand on a global level. Implementation of cutting-edge technology in healthcare sector and increasing investment in research and development have contributed significantly to revenue growth of the market in the recent past. In addition, availability of favorable health insurance and reimbursement policies have also positively impacted the healthcare sector with more and more individuals opting to get treatment at hospital and clinical facilities. Rapid development of novel drugs and pharmaceuticals, increasing incidence of lifestyle and chronic diseases, establishment of state-of-the-art healthcare facilities, and rising availability of over-the-counter medications have significantly contributed to the revenue growth of the market.  

Major Highlights of the Atrial Fibrillations Market Report:

• EP ablation catheters segment is expected to account for a significantly large revenue share in the global market over the forecast period attributable to rising preference for catheter ablation for diagnosis and treatment of atrial fibrillation. Atrial fibrillation is considered as the most promising indication for cardiac ablation owing to its increasing unresponsiveness to existing treatment and growing prevalence across the globe.
• Hospitals segment is expected to register robust revenue CAGR over the forecast period owing to increasing patient admissions in hospitals, rising number of catheter ablation procedures performed in hospital settings, availability of skilled professionals and state-of-the-art healthcare infrastructure, advanced post-operative facilities, and growing preference for minimally invasive surgical procedures.
• North America is expected to account for largest revenue share between 2021 and 2028 attributable to increasing number of atrial fibrillation treatment procedures performed due to rising incidence of cardiovascular diseases, growing investment to advance clinical treatment of atrial fibrillation, availability of robust healthcare infrastructure and facilities, implementation of favorable reimbursement policies, and increasing FDA approvals for medical devices and treatment.
• Companies profiled in the global market report include Abbott Laboratories, Atricure Inc., Johnson Johnson, Microport Scientific Corporation, Boston Scientific Corporation, Biosense Webster, Inc., St. Jude Medical, Inc., Siemens AG, Medtronic Plc, Koninklijke Philips N.V., Cardiofocus, Inc., Biotitic Se Co. Kg, Inc., Carima, Inc., Ncontact, Inc., and Agricore, Inc.
• In September 2021, Match Health Academy, which is an online learning platform, announced the launch of three online video courses offered by experts to educate patients and their families understand atrial fibrillation and help them in managing it. Match Health Academy offers online learning with self-paced courses that help patients and their families improve their knowledge and understanding of health conditions and available treatment approaches.

Additionally, the report consists a detailed analysis of the segmentation of the Atrial Fibrillations Market based on product types and end-use/application offered in the Atrial Fibrillations Market -

Type Outlook (Revenue, USD Billion; 2018-2028)

• EP Ablation Catheters
• Cardiac Monitors
• EP Diagnostic Catheter
• Mapping and Recording Systems
• Access Devices
• Intracardiac Echocardiography

End-Use Outlook (Revenue, USD Billion; 2018-2028)

• Hospitals
• Cardiac Centers
• Ambulatory Care Centers

Key Regional Markets Studied in the Report:

• North America (U.S., Canada)
• Europe (U.K., Italy, Germany, France, Rest of EU)
• Latin America (Chile, Brazil, Argentina, Rest of Latin America)
• Asia Pacific (India, Japan, China, South Korea, Australia, Rest of APAC)
• The Middle East Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.

Request for Customization this report - https://www.reportsanddata.com/request-customization-form/1440